表紙
市場調査レポート

生体イメージング用試薬:技術と世界市場

Biologic Imaging Reagents: Technologies and Global Markets

発行 BCC Research 商品コード 78812
出版日 ページ情報 英文 189 pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
生体イメージング用試薬:技術と世界市場 Biologic Imaging Reagents: Technologies and Global Markets
出版日: 2013年01月01日 ページ情報: 英文 189 pages
概要

当レポートでは、世界の生体イメージング用試薬市場について、上市薬および今後5年以内に上市が見込まれる製品を含めて調査分析しており、世界市場の動向、データ、推計および今後のCAGR予測、各種技術の分析・比較、アプリケーション分野の動向、産業構造、主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • イントロダクション
  • 調査範囲
  • 市場潜在性
  • 産業の成長促進因子
  • ライフサイクル状況
  • 生体イメージング用試薬産業

第4章 生体イメージング技術

  • イメージング用試薬の種類
  • インビボイメージング手法
  • 分子イメージング
  • インビトロイメージング/検出
  • インビボイメージングの動向
  • 生体イメージング用試薬の技術
  • イメージング用試薬の新しいクラス
  • 生体イメージング用試薬の製造コスト
  • イメージング用試薬技術プラットフォームの比較

第5章 生体イメージング用試薬のアプリケーション

  • 概要
  • R&D
  • 創薬・薬剤開発
  • 診断

第6章 生体イメージング用試薬の産業構造

  • イメージング用試薬産業における革新
  • 戦略的アライアンス
  • 産業買収
  • 医療イメージング装置部門
  • 蛍光色素・プローブ産業の構造
  • 量子ドット産業
  • コントラスト試薬産業
  • 放射性医薬品産業
  • 小動物インビボイメージング産業
  • 心臓イメージング産業
  • 前立腺癌イメージング産業
  • アルツハイマー病PETイメージング産業

第7章 生体イメージング用試薬市場

  • 成長促進因子
  • 市場概要
  • コントラスト試薬市場
  • 放射性医薬品市場
  • 光学イメージング用試薬市場
  • 地域市場

第7章 特許状況

  • イメージング用試薬特許:主要技術別
  • 特許のサマリー:企業別

第8章 企業プロファイル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO064B

Abstract

REPORT HIGHLIGHTS

This report provides:

An overview of the global market for biologic imaging reagents, including those that are commercial or likely to be commercialized within the next five years

Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017

Coverage of fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; supermolecules; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals

Analysis of each technology to determine its market status and impact on future market segments

Discussion of imaging reagent producers and the industry structure in specialized segments

Reviews of industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and R&D tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis

Comprehensive company profiles of major players in the industry.

image1

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC's goal for this study was to determine the global market and future demand growth for biologic imaging reagents over a five-year period from 2012 to 2017. Our particular interest is to characterize and quantify the biologic imaging reagents market potential by technology, reagent type and end user market. We also evaluate future growth opportunities in emerging biologic imaging reagents including quantum dots, nanoparticles, fluorescent proteins and supermolecules.

Imaging reagent types covered include fluorescent probes and dyes; fluorescent proteins; nanoparticles; magnetic resonance imaging, ultrasound and X-ray contrast reagents; and imaging radiopharmaceuticals.

Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biologic imaging reagents and forecast the future commercial potential for the key market segments. This discussion will provide a basis for companies to make strategic choices about developing new products and markets, or employing biologic imaging reagents. The study will benefit reagent and instrument manufacturers, users of biologic imaging reagents, medical instrument companies, life sciences tools companies, diagnostic and drug manufacturers, biotechnology companies, and developers of nanotechnologies.

REASONS FOR DOING THE STUDY

Biologic imaging reagents play an important role in the medical, pharmaceutical, diagnostic, biotechnology and life sciences tools industries. Imaging and detection technologies are used extensively in medicine, biotechnology and pharmaceutical research. Traditional imaging techniques, such as X-ray, computer tomography (CT), ultrasound (US), magnetic resonance imaging (MRI) and nuclear medicine (NM), mainly analyze anatomy and morphology and cannot detect changes at the molecular level. However, new developments in biotechnology allow us to image at the cellular and molecular level, paving the way for earlier diagnosis and treatment of disease. Biologic imaging reagents play a critical role in this medical revolution.

At the same time, ongoing advances in genomics, proteomics and cellular analysis are aided by imaging technologies, including fluorescent dyes and probes, quantum dot nanoparticles, and fluorescent proteins. Growth in technologies such as biochips, DNA sequencing and polymerase chain reaction (PCR) relies on sensitive biologic fluorescent imaging reagents.

Advances in technologies that are used in biologic imaging reagents are also moving forward at a rapid pace. These technologies include nanotechnology, biologic targeting, microfluidics, supramolecular chemistry and protein engineering. Rapid developments across a number of technology fields promise to change the biologic imaging industry by enabling novel imaging reagents and unique market opportunities. This report analyzes these developments and their impact on the future markets for biologic imaging reagents.

Given these market and technology dynamics, it is especially timely to examine the biologic imaging reagents market.

CONTRIBUTION OF THE STUDY AND FOR WHOM

We have compiled a study of existing and future imaging reagent technologies that will be commercially important in the major end user segments, including life science research tools, drug discovery and development, and diagnostics.

We present the various imaging reagent technologies, including fluorescent probes and dyes, nanomaterials, fluorescent proteins, contrast reagents, and imaging radiopharmaceuticals. We also examine the industry growth driving forces; product types; market applications; companies and industry alliances and acquisitions; future market potential; and product sales forecasts for the period 2012 through 2017. We project the future use of biologic imaging reagents in the main end user segments and by technology.

This study will be of particular interest to life science research tools suppliers, pharmaceutical manufacturers, diagnostics, biotechnology, genomics, proteomics, nanotechnology and supramolecular companies. It will also be of interest to companies making products for medical imaging, microarrays, lab on a chip, polymerase chain reaction, molecular diagnostics assays, cell-based assays, and fluorescence activated cell sorting (FACS) as well as medical researchers and clinicians.

SCOPE AND FORMAT

The study scope includes the biologic imaging reagents that are commercial or likely to be commercialized within the next five years. Fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals are studied. Both the in-vivo and in-vitro market segments are included. Each technology is analyzed to determine its market status, impact on future market segments and forecasted growth from 2012 through 2017. Technology status and market driving forces are also discussed.

BCC examines imaging reagent producers and the industry structure in specialized segments of the industry. We also review industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and research and development (R&D) tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis. The markets for novel biologic imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents, are analyzed, and the main companies in these fields are highlighted.

METHODOLOGY

BCC talked to key users and producers in the end user market segments and technology fields that will be commercially important during the next five years. Extensive secondary market research was performed.

Based on our analysis, we project the future applications of biologic imaging reagents in the major end user market segments and by technology type and forecast sales revenues for 2012 through 2017.

INFORMATION SOURCES

BCC surveyed academic, government and industrial institutions to obtain data for this study. Included were life science research tools, pharmaceutical, diagnostic, biotechnology and nanotechnology firms, and leading life science research institutions. We also spoke with leading industry thought leaders. In addition, we compiled data from secondary sources, including industry, trade and government.

ANALYST CREDENTIALS

The author, John Bergin, has written numerous BCC biotechnology reports on genomics, microarrays, DNA sequencing, synthetic biology, epigenomics and diagnostics.

Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with an emerging separations company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology and Masters of Business Administration.

Table of Contents

Chapter- 1: INTRODUCTION - Complimentary

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • RELATED BCC REPORTS
  • ANALYST CREDENTIALS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY

  • Table Summary : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH 2017
  • Figure Summary : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH 2017

Chapter- 3: OVERVIEW

  • INTRODUCTION
  • REPORT SCOPE
  • MARKET POTENTIAL
  • INDUSTRY GROWTH DRIVING FORCES
  • LIFE CYCLE STATUS
  • BIOLOGIC IMAGING REAGENTS INDUSTRY

Chapter- 4: BIOLOGIC IMAGING TECHNOLOGIES

  • IMAGING REAGENT TYPES
  • IN-VIVO IMAGING MODALITIES
  • MOLECULAR IMAGING
  • IN-VITRO IMAGING/DETECTION
  • TRENDS IN IN-VIVO IMAGING
  • BIOLOGIC IMAGING REAGENTS TECHNOLOGIES
  • EMERGING CLASSES OF IMAGING REAGENTS
  • BIOLOGIC IMAGING REAGENTS MANUFACTURING COSTS
  • COMPARISON OF IMAGING REAGENT TECHNOLOGY PLATFORMS

Chapter- 5: BIOLOGIC IMAGING REAGENTS APPLICATIONS

  • OVERVIEW
  • RESEARCH AND DEVELOPMENT
  • DRUG DISCOVERY AND DEVELOPMENT
  • DIAGNOSTICS

Chapter- 6: BIOLOGIC IMAGING REAGENTS INDUSTRY STRUCTURE

  • INNOVATION WITHIN THE IMAGING REAGENT INDUSTRY
  • STRATEGIC ALLIANCES
  • INDUSTRY ACQUISITIONS
  • MEDICAL IMAGING INSTRUMENT SECTOR
  • FLUORESCENT DYES AND PROBES INDUSTRY STRUCTURE
  • QUANTUM DOTS INDUSTRY
  • CONTRAST REAGENTS INDUSTRY
  • RADIOPHARMACEUTICALS INDUSTRY
  • SMALL ANIMAL IN-VIVO IMAGING INDUSTRY
  • CARDIAC IMAGING INDUSTRY
  • PROSTATE CANCER IMAGING INDUSTRY
  • ALZHEIMER'S DISEASE PET IMAGING INDUSTRY

Chapter- 7: BIOLOGIC IMAGING REAGENTS MARKETS

  • GROWTH DRIVING FORCES
  • MARKET OVERVIEW
  • CONTRAST REAGENTS MARKET
  • RADIOPHARMACEUTICALS MARKET
  • OPTICAL IMAGING REAGENTS MARKET
  • GEOGRAPHICAL MARKET

Chapter- 8: PATENT STATUS

  • IMAGING REAGENTS PATENTS BY SELECTED TECHNOLOGY
  • SUMMARY OF PATENTS BY COMPANY

Chapter- 9: COMPANY PROFILES

  • ABT MOLECULAR IMAGING INC.
  • ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
  • ACTIVE MOTIF CHROMEON GMBH
  • ACUSPHERE INC.
  • ADVANCED ACCELERATOR APPLICATIONS SA
  • ADVANCED PROTEOME THERAPEUTICS INC.
  • ADVANCED RESEARCH TECHNOLOGIES, INC.
  • AFFIBODY AB
  • AGENIX LTD.
  • ALSERES PHARMACEUTICALS INC.
  • ALZHYME PTY LTD.
  • AMAG PHARMACEUTICALS INC.
  • AMERICAN ELEMENTS
  • AMERICAN DYE SOURCE INC.
  • ANASPEC INC.
  • ANTICANCER INC.
  • APOSENSE
  • AREVA
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA LTD.
  • ATREUS PHARMACEUTICALS CORPORATION
  • ATTO-TEC GMBH
  • AXXAM SPA
  • BAYER HEALTHCARE AG
  • BBI INTERNATIONAL
  • BD
  • BECKMAN COULTER INC.
  • BETAPLUS RADIOPHARMACEUTIALS LLC
  • BIOFORCE NANOSCIENCES HOLDINGS INC.
  • BIOMODA INC.
  • BIOSCAN INC.
  • BIOSEARCH TECHNOLOGIES INC.
  • BIOSCEPTRE INTERNATIONAL LIMITED
  • BIOTIUM INC.
  • BIOVISION, INC.
  • BRACCO IMAGING S.P.A.
  • CAPSULUTION PHARMA AG
  • CARDINAL HEALTH
  • CARESTREAM HEALTH INC.
  • CELLCYTE GENETICS
  • CELLPOINT LLC.
  • CHEMATECH SAS
  • CHEMICELL GMBH
  • CHINA MEDICAL TECHNOLOGIES INC.
  • CHROMOTEK GMBH
  • CISBIO BIOASSAYS
  • COVALYS BIOSCIENCES AG
  • COVIDIEN PLC
  • CYTODIAGNOSTICS
  • DAIICHI SANKYO CO. LTD.
  • DENDRITECH INC.
  • DENOVO BIOLABELS GMBH
  • EBIOSCIENCE INC.
  • ECKERT & ZIEGLER AG
  • ELI LILLY AND COMPANY
  • ERIGAL LIMITED
  • ESTECH PHARMA CO. LTD.
  • EVIDENT TECHNOLOGIES
  • EVROGEN
  • FERROPHARM GMBH
  • FLUOPTICS
  • FLUOROPHARMA INC.
  • FUJI PHARMA CO. LTD.
  • GE HEALTHCARE
  • GENISPHERE LLC
  • GUERBET
  • IASON GMBH
  • IMAGINAB INC.
  • IMMUNOMEDICS INC.
  • INDEC BIOSYSTEMS
  • INNOPROT
  • INVISAGE INC.
  • IPSEN GROUP
  • ISO-TEX DIAGNOSTICS INC.
  • JAZZ PHARMACEUTICALS PLC
  • J.B. CHEMICALS & PHARMACEUTICALS LTD.
  • JOHNSON & JOHNSON
  • JUBILANT LIFE SCIENCES LTD.
  • KEREOS INC.
  • KPL INC.
  • LAB21 LTD
  • LABORATOIRES CYCLOPHARMA
  • LANTHEUS MEDICAL IMAGING
  • LIFE TECHNOLOGIES INC.
  • LUMIPHORE INC.
  • LUNA NANOWORKS
  • MARINPHARM GMBH
  • MARVAL BIOSCIENCES INC.
  • MBL INTERNATIONAL
  • MEDI RADIOPHARMA LTD
  • MELLITECH SAS
  • MOBIOTEC GMBH
  • MOLECULAR INSIGHT PHARMACEUTICALS
  • MOLECULAR TARGETING TECHNOLOGIES INC.
  • NANOAXIS LLC
  • NANOCO TECHNOLOGIES LTD.
  • NANO-H SAS
  • NANOPROBES INC.
  • NANOSCAN IMAGING LLC
  • NANOSPECTRA BIOSCIENCES
  • NANOSPHERE INC.
  • NAVIDEA BIOPHARMACEUTICALS
  • NN-LABS LLC
  • NORDION INC.
  • NOVELOS THERAPEUTICS INC.
  • NUVIEW LIFE SCIENCES
  • OCEAN NANOTECH LLC
  • OCTREOPHARM SCIENCES GMBH
  • OXFORD CONTRAST MOLECULAR DIAGNOSTICS
  • OXONICA INC.
  • PERKINELMER INC.
  • PHARMALUCENCE INC.
  • PHILIPS HEALTHCARE
  • PHOTOCURE ASA
  • PIRAMAL HEALTHCARE LTD.
  • PRINCIPIO, INC.
  • PROMEGA CORPORATION
  • QUANTUM MATERIALS CORPORATION
  • RAPIDSCAN PHARMA SOLUTIONS INC.
  • READE ADVANCED MATERIALS
  • SIEMENS AG
  • SIRIGEN LTD.
  • SIGNALOMICS GMBH
  • SPAGO IMAGING AB
  • SOFIE BIOSCIENCES
  • TAKARA BIO INC.
  • TAEJOON PHARMA CO. LTD.
  • TARGESON INC.
  • THERAGNOSTIC TECHNOLOGIES INC.
  • THERMO FISHER SCIENTIFIC
  • TK-SIGNAL LTD.
  • TOP SRL
  • WILEX AG

List of Tables

  • Summary Table : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH 2017
  • Table 1 : SCOPE OF THIS REPORT
  • Table 2 : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS, THROUGH 2017
  • Table 3 : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY END USER MARKET, THROUGH 2017
  • Table 4 : BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
  • Table 5 : LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS
  • Table 6 : BIOLOGIC IMAGING REAGENTS KEY COMPANIES
  • Table 7 : KEY BIOLOGIC IMAGING REAGENT TYPES
  • Table 8 : IN-VIVO IMAGING MODALITIES
  • Table 9 : COMPARISON OF IN-VIVO IMAGING MODALITIES
  • Table 10 : APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING
  • Table 11 : KEY TECHNOLOGY DRIVERS FOR IN-VIVO IMAGING REAGENTS
  • Table 12 : NANOPARTICLES IN IMAGING APPLICATIONS
  • Table 13 : FLUORESCENT DYES AND PROBES
  • Table 14 : GENERAL ADVANTAGES OF FLUORESCENCE LABELS
  • Table 15 : FLUORESCENT DYE PERFORMANCE CRITERIA
  • Table 16 : TYPES OF FLUORESCENT PROTEINS
  • Table 17 : PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES
  • Table 18 : EMERGING APPLICATIONS OF FLUORESCENT PROTEINS
  • Table 19 : FLUORESCENT PROTEINS VERSUS DYES
  • Table 20 : TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS
  • Table 21 : CLASSIFICATION OF IMAGING SUPERMOLECULES
  • Table 22 : COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT PROTEINS
  • Table 23 : BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS
  • Table 24 : MICROBUBBLE ULTRASOUND IMAGING AGENTS
  • Table 25 : EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS
  • Table 26 : LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES
  • Table 27 : TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS
  • Table 28 : TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS
  • Table 29 : BIOLOGIC IMAGING REAGENTS APPLICATIONS
  • Table 30 : SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND MEDICAL INDUSTRIES
  • Table 31 : USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT
  • Table 32 : APPLICATIONS WITHIN MARKET SEGMENTS
  • Table 33 : R&D TOOLS IMAGING REAGENTS
  • Table 34 : EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS
  • Table 35 : IMAGING APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT
  • Table 36 : COMPARISON OF SMALL ANIMAL IMAGING MODALITIES
  • Table 37 : OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING
  • Table 38 : DIAGNOSTICS IMAGING REAGENTS APPLICATIONS
  • Table 39 : DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS
  • Table 40 : CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING
  • Table 41 : BIOLOGIC IMAGING REAGENT STRATEGIC ALLIANCES, 2010-2012
  • Table 42 : BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2010 - 2012
  • Table 43 : COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES
  • Table 44 : FLUORESCENT IMAGING REAGENTS COMPETITORS
  • Table 45 : QUANTUM DOT COMPETITORS
  • Table 46 : CONTRAST AGENTS KEY COMPETITORS
  • Table 47 : IMAGING RADIOPHARMACEUTICALS COMPANIES
  • Table 48 : RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES
  • Table 49 : SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING REAGENT COMPETITORS
  • Table 50 : CARDIAC IMAGING REAGENT COMPETITIVE SPACE
  • Table 51 : PROSTATE CANCER IMAGING AGENT COMPETITION
  • Table 52 : ALZHEIMER'S DISEASE PET IMAGING AGENT COMPETITIVE SPACE
  • Table 53 : BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES
  • Table 54 : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY APPLICATION, THROUGH 2017
  • Table 55 : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS, THROUGH 2017
  • Table 56 : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS MARKET, BY END USE, THROUGH 2017
  • Table 57 : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2017
  • Table 58 : GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY MODALITY, THROUGH 2017
  • Table 59 : GLOBAL VALUE OF CONTRAST REAGENTS MARKET, BY MODALITY, THROUGH 2017
  • Table 60 : GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE, THROUGH 2017
  • Table 61 : GLOBAL VALUE OF GD-CHELATE MRI REAGENTS BY PRODUCT, THROUGH 2017
  • Table 62 : GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, THROUGH 2017
  • Table 63 : GLOBAL SALES OF MRI CONTRAST REAGENTS BY PROCEDURE, THROUGH 2017
  • Table 64 : GLOBAL VALUE OF MICROBUBBLE ULTRASOUND REAGENTS MARKET, BY TYPE, THROUGH 2017
  • Table 65 : GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY TYPE, THROUGH 2017
  • Table 66 : GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY INDICATION, THROUGH 2017
  • Table 67 : GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY SCANNER TYPE, THROUGH 2017
  • Table 68 : GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH 2017
  • Table 69 : GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2017
  • Table 70 : GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY TECHNOLOGY, THROUGH 2017
  • Table 71 : GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH 2017
  • Table 72 : HALF LIFE OF COMMON PET AND SPECT ISOTOPES
  • Table 73 : GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2017
  • Table 74 : SENTINEL NODE DETECTION RADIOPHARMACEUTICALS PRODUCERS
  • Table 75 : GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY TECHNOLOGY, THROUGH 2017
  • Table 76 : GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH 2017
  • Table 77 : GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY INDICATION, THROUGH 2017
  • Table 78 : GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY TECHNOLOGY, THROUGH 2017
  • Table 79 : GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY APPLICATION, THROUGH 2017
  • Table 80 : GLOBAL VALUE OF IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017
  • Table 81 : GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017
  • Table 82 : GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017
  • Table 83 : GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS MARKET BY ASSAY TYPE, THROUGH 2017
  • Table 84 : GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE, THROUGH 2017
  • Table 85 : GLOBAL VALUE OF IN-VITRO OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH 2017
  • Table 86 : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH 2017
  • Table 87 : NUMBER OF PATENTS BY TECHNOLOGY, 2001-2011
  • Table 88 : FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY
  • Table 89 : FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY
  • Table 90 : QUANTUM DOTS PATENT ASSIGNEES BY COMPANY
  • Table 91 : GOLD NANOPARTICLE PATENT ASSIGNEES BY COMPANY
  • Table 92 : NUMBER OF PATENTS, BY COMPANY, FOR FOUR IMAGING REAGENT MARKET SEGMENTS
  • Table 93 : AFFIBODY ALLIANCES
  • Table 94 : FLUORPHARMA PET IMAGING REAGENT PIPELINE
  • Table 95 : KEREOS IMAGING REAGENTS PIPELINE
  • Table 96 : LANTHEUS DIAGNOSTIC IMAGING PIPELINE
  • Table 97 : MOLECULAR INSIGHT IMAGING REAGENTS PIPELINE
  • Table 98 : LYMPH NODE STATUS
  • Table 99 : NANOSPHERE GOLD IMAGING REAGENTS PIPELINE
  • Table 100 : NAVIDEA PIPELINE
  • Table 101 : WILEX CLINICAL PRODUCT PIPELINE

List of Figures

  • Summary Figure : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH 2017
  • Figure SAMPLE FIGURE : GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH 2017
  • Figure 1 : QUANTUM DOT SPECTRA
  • Figure 2 : FLUORESCENT DYE SPECTRA
  • Figure 3 : THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY
  • Figure 4 : ESTIMATED MANUFACTURING COSTS OF IMAGING REAGENTS CLASSES
  • Figure 5 : ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT
Back to Top